Covid-19 - Third wave likely to come late: ICMR study says
Trial for Zydus Cadila vaccine is almost complete, Dr NK Arora, Chairman, COVID working group has said adding that by July end or in August, the government might be able to start administering this vaccine to children of 12-18 age group
Indian Council of Medical Research (ICMR) has come up with a study which says that a third wave is likely to come late.
Trial for Zydus Cadila vaccine is almost complete, Dr NK Arora, Chairman, COVID working group has said adding that by July end or in August, the government might be able to start administering this vaccine to children of 12-18 age group.
He further said that there is a window period of 6-8 months to immunise everybody in the country. “In coming days, our target is to administer 1 crore doses every day,” Arora said.
Meanwhile, Arora, has told IANS that vaccination along with Covid appropriate behaviour will play a crucial role in minimizing the effect of subsequent wave.
"The analysis indicates that vaccines almost all Covid vaccines, be it India made or overseas, are highly effective against Covid. Not 100 per cent but, now it has proved that vaccines will minimise the damage. Even if it reduces the number of deaths, it means that we have something to control deadly pandemic. So, the vaccination is going to play a very important role in the next wave," Arora Said and IANS reported.
Arora, however, added that it will also depend on new variants and their level of transmission and effectiveness, as every new variant, emerging one after another, is different, this report said.
The first wave of Covid-19 pandemic in India had begun in late January 2020 with a peak attained in mid-September. The first wave was relatively mild compared to the second wave that followed, from mid-February 2021 onwards, exhibiting a more explosive spread across the country, this report said.
Dr Arora further said that a major factor behind the deadly second wave was emergence of more-infectious variants such as B.1.1.7 (Alpha variant) and B.1.617.2 (Delta variant), of which the latter has played a dominant role in recent months.
Recently, ICMR along with Imperial College London (UK) has also conducted a study on rapid scale-up of vaccination efforts, which according to Dr Arora, could play an important role in mitigating the present and future waves of the disease, this IANS report said.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
05:16 PM IST